Don A. Stevens

6.7k total citations
100 papers, 798 citations indexed

About

Don A. Stevens is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Don A. Stevens has authored 100 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 46 papers in Pathology and Forensic Medicine and 45 papers in Genetics. Recurrent topics in Don A. Stevens's work include Lymphoma Diagnosis and Treatment (45 papers), Chronic Lymphocytic Leukemia Research (44 papers) and CAR-T cell therapy research (34 papers). Don A. Stevens is often cited by papers focused on Lymphoma Diagnosis and Treatment (45 papers), Chronic Lymphocytic Leukemia Research (44 papers) and CAR-T cell therapy research (34 papers). Don A. Stevens collaborates with scholars based in United States, Italy and United Kingdom. Don A. Stevens's co-authors include John P. Greer, Luis Piñeiro, David B. Miklos, Sattva S. Neelapu, John M. Burke, Mehdi Hamadani, Habte Yimer, BJ Bolwell, RH Herzig and Keqin Qi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Don A. Stevens

89 papers receiving 786 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Don A. Stevens United States	15	469	234	232	223	149	100	798
Kathleen Dorritie United States	15	466 1.0×	166 0.7×	149 0.6×	179 0.8×	181 1.2×	45	773
Joseph Alvarnas United States	12	342 0.7×	270 1.2×	158 0.7×	174 0.8×	83 0.6×	31	880
Kitsada Wudhikarn Thailand	14	541 1.2×	125 0.5×	136 0.6×	162 0.7×	57 0.4×	55	742
Xia Mao China	16	512 1.1×	235 1.0×	84 0.4×	194 0.9×	53 0.4×	66	741
Jonathan E. Brammer United States	16	423 0.9×	179 0.8×	322 1.4×	210 0.9×	121 0.8×	112	888
Reuben Benjamin United Kingdom	19	498 1.1×	374 1.6×	62 0.3×	168 0.8×	107 0.7×	43	1.1k
Quanshun Wang China	10	755 1.6×	285 1.2×	142 0.6×	176 0.8×	50 0.3×	63	1.0k
Reinhard Marks Germany	15	301 0.6×	136 0.6×	194 0.8×	423 1.9×	115 0.8×	55	793
Nancy M. Hardy United States	15	426 0.9×	106 0.5×	109 0.5×	374 1.7×	93 0.6×	63	784
B. Gahn Germany	12	455 1.0×	84 0.4×	295 1.3×	127 0.6×	137 0.9×	21	775

Countries citing papers authored by Don A. Stevens

Since Specialization

Citations

This map shows the geographic impact of Don A. Stevens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don A. Stevens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don A. Stevens more than expected).

Fields of papers citing papers by Don A. Stevens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don A. Stevens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don A. Stevens. The network helps show where Don A. Stevens may publish in the future.

Co-authorship network of co-authors of Don A. Stevens

This figure shows the co-authorship network connecting the top 25 collaborators of Don A. Stevens. A scholar is included among the top collaborators of Don A. Stevens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don A. Stevens. Don A. Stevens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patnaik, Mrinal M., Haris Ali, Eunice S. Wang, et al.. (2025). Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. PubMed. 2(4). 100115–100115.

Locke, Frederick L., Javier Muñoz, Michael Tees, et al.. (2025). Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. Journal of Clinical Oncology. 43(14). 1695–1705. 11 indexed citations

Ghia, Paolo, İnci Alacacıoğlu, Dennis Carney, et al.. (2025). Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY. Blood. 146(Supplement 1). 3898–3898.

Grieselhuber, Nicole R., Anjali S. Advani, Abdulraheem Yacoub, et al.. (2024). PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study. Blood. 144(Supplement 1). 1840–1840.

Iyer, Swaminathan P., Ranjit Nair, Neha Mehta–Shah, et al.. (2024). A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma. Blood. 144(Supplement 1). 4449–4449. 1 indexed citations

Budde, Lihua E., Don A. Stevens, Gary J. Schiller, et al.. (2024). Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.. Journal of Clinical Oncology. 42(16_suppl). 7077–7077.

Gaballa, Sameh, Jing‐Zhou Hou, Sumana Devata, et al.. (2024). Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients. Blood. 144(Supplement 1). 868–868. 4 indexed citations

Hou, Jing‐Zhou, Ranjit Nair, Ryan Jacobs, et al.. (2024). Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma. Blood. 144(Supplement 1). 341–341. 9 indexed citations

Nair, Ranjit, Ryan Jacobs, Sumana Devata, et al.. (2023). HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY. Hematological Oncology. 41(S2). 127–129. 1 indexed citations

10.

Lue, Jennifer Kimberly, Don A. Stevens, Emmeline Ayers, et al.. (2023). PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS. Hematological Oncology. 41(S2). 808–809.

11.

Zinzani, Pier Luigi, Jiřı́ Mayer, Ohad Benjamini, et al.. (2023). A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006. Hematological Oncology. 41(S2). 564–565. 2 indexed citations

12.

Belada, David, Kateřina Kopečková, Juan Bergua, et al.. (2023). Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 142(16). 1348–1358. 12 indexed citations

13.

Daver, Naval, Anthony S. Stein, Dale L. Bixby, et al.. (2023). Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). Blood. 142(Supplement 1). 4278–4278. 4 indexed citations

14.

Godwin, John E., César O. Freytes, Michael B. Maris, et al.. (2021). Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 27(3). S203–S204. 1 indexed citations

15.

Morschhauser, Franck, Nilanjan Ghosh, Izidore S. Lossos, et al.. (2021). Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood Cancer Journal. 11(8). 147–147. 16 indexed citations

16.

Iyer, Swaminathan P., Auris Huen, Weiyun Z. Ai, et al.. (2021). Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. Blood. 138(Supplement 1). 1365–1365. 12 indexed citations

17.

Hawkes, Eliza A., Tycel Phillips, Lihua E. Budde, et al.. (2021). Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. Targeted Oncology. 16(6). 761–771. 10 indexed citations

18.

Spalding, Aaron C., et al.. (2018). Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib. Experimental Hematology and Oncology. 7(1). 20–20. 5 indexed citations

19.

Fleming, Donald R., et al.. (2000). Mobilization of Peripheral Blood Stem Cells in High-Risk Breast Cancer Patients Using G-CSF After Standard Dose Docetaxel. Journal of Hematotherapy & Stem Cell Research. 9(6). 855–860. 6 indexed citations

20.

Fleming, Donald R., et al.. (1999). Dose-Intensive Chemotherapy for Breast Cancer With Brain Metastases. American Journal of Clinical Oncology. 22(4). 371–374. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact